Across TCGA pan-cancer cohorts, IGHD2-21 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of IGHD2-21’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGHD2-21 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGHD2-21 is over-expressed in tumor, although a few such as PAAD and COAD show the opposite, repressed pattern.

HNSC, LUAD, and PAAD are the cancer types where IGHD2-21 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHD2-21 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.349	.016	6	view →
LUAD	All	IV	+2.105	.002	4	view →
PAAD	Female	All	−2.840	.038	2	view →
COAD	All	II,III,IV	−0.442	.049	2	view →
STAD	Male	IV	−2.844	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHD2-21 RNA expression & survival · all IGHD2-21 data types